Introduction {#Sec1}
============

Recent research in neurodegenerative disease has highlighted the importance of a new molecular entity, the TAR DNA binding protein, TDP-43 (see \[[@CR6]\] for review). Prior to the discovery in 2006 that TDP-43 was the target protein in the ubiquitinated cytoplasmic inclusions in neurones in certain histological forms of frontotemporal lobar degeneration (FTLD) known as FTLD-ubiquitinated (FTLD-U), and in motor neurone disease (MND) \[[@CR2], [@CR24]\], little was known of the function of this 414 amino acid nuclear protein beyond it serving a role in nuclear transcription in relationship to alternative splicing or exon skipping \[[@CR5], [@CR30]\] The involvement of TDP-43 in the ubiquitinated lesions of FTLD-U and MND has now been amply confirmed \[[@CR6], [@CR7], [@CR9], [@CR17], [@CR29]\]. While ubiquitinated TDP-43 lesions are characteristically seen in those patients with inherited forms of FTLD associated with mutations in progranulin gene (*PGRN*) \[[@CR3], [@CR4], [@CR8], [@CR9], [@CR16], [@CR26], [@CR28]\], in other patients with FTLD, such as those with mutations in tau gene (*MAPT*), or in those with a Pick body-type histology, where the underlying histology is based on the accumulation of aggregated tau proteins, no such TDP-43 pathological changes are seen \[[@CR9]\]. Moreover, other studies have shown that TDP-43 pathological changes can also occur in about 20% of patients with Alzheimer's disease (AD) \[[@CR1]\] and are widely present in patients with Lewy body diseases \[[@CR21]\] or with parkinsonism-dementia complex of Guam \[[@CR12]\].

Present data therefore suggest a widespread involvement of TDP-43 in neurodegenerative disease beyond FTLD-U and MND. In clinical terms, about 70% of patients with FTLD show behavioural and personality changes which are collectively described as frontotemporal dementia (FTD) \[[@CR23]\]. Prospective and retrospective pathological studies have indicated that about half of all cases with FTD have a tau-positive, TDP-43-negative pathology, and half have ubiquitin-positive, TDP-43-positive pathology \[[@CR10], [@CR14], [@CR15], [@CR20], [@CR27]\]. Nevertheless, in patients with FTLD, it is presently not possible to predict, in life, what the underlying histological changes might be solely on the basis of clinical phenotype, and it is only in that minority of patients where mutations in *MAPT* or *PGRN* are present that a tau or ubiquitin/TDP-43 based histology, respectively, can be confidently inferred.

The differential diagnosis of dementia syndromes is clinical and radiological, and there are no litmus tests based on measures in blood or plasma to specify diagnosis. A biochemical marker that could distinguish between AD and FTLD, or between the histological subtypes of FTLD, would be not only of great diagnostic value, but would be highly pertinent to the future development of drugs aimed at preventing or removing the intraneuronal accumulation of tau or TDP-43 proteins in these degenerative disorders. Given the pathological observations that a proportion of patients with AD \[[@CR1]\] or FTLD \[[@CR9], [@CR14], [@CR15], [@CR19], [@CR27]\] harbour TDP-43 pathological changes within their brains, it can be hypothesised that similar proportions of patients might show altered blood or plasma levels of TDP-43, and that this could be a useful biomarker of the presence of TDP-43 brain pathology.

In this present study we have investigated whether TDP-43 can be detected in plasma in patients with FTD and AD, and in normal control subjects, by developing an ELISA-based assay. We show that not only can TDP-43 be detected in plasma, but more importantly, that the level of this is elevated in a proportion of each group of patients similar to that seen in patients with known TDP-43 brain pathology. Measurement of plasma TDP-43 may therefore have utility in evidencing the presence of brain TDP-43 based pathologies in neurodegenerative disease, and perhaps more importantly be capable of discriminating during life those patients with FTLD associated with ubiquitin/TDP-43 pathological changes in their brains from those with tauopathy, when a defining mutation in *MAPT* or *PGRN* is absent.

Materials and methods {#Sec2}
=====================

Blood samples {#Sec3}
-------------

Blood samples were obtained with Ethical permissions from 137 patients, 35 with FTD and 102 with AD, and 85 non-demented control subjects (Table [1](#Tab1){ref-type="table"}). All patients with FTD and AD had been assessed (by DN, JSS) within out-patient clinics at the Cerebral Function Unit, Greater Manchester Neurosciences Centre. All patients had undergone historical interview in the presence of a family caregiver and comprehensive cognitive assessment to obtain information about the nature and progression of cognitive and functional decline. Patients with AD and FTD fulfilled the National Institute of Neurological and Communicative Disorders and Stroke---Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD \[[@CR18]\] and International criteria for FTD \[[@CR22]\], respectively. Control subjects were either spouses of patients attending CFU clinic (*n* = 13), or a sample of healthy volunteers (*n* = 72) drawn randomly from a cohort of 767 mentally normal people aged \>50 years, resident within the same Greater Manchester region from which the AD and FTD patients were recruited \[[@CR25]\]. The latter comprised a longitudinal ageing study group who had been screened psychologically for absence of cognitive impairment consistent with dementia. All blood samples had been collected with the approval of the local ethics research committee.Table 1Details of groups of patients with AD and FTD, and control subjects, at the time when blood samples were takenControlADFTDPatients (*n*)8510235Age range (years)42--8343--8842--78Mean age (years) ± SD71.3 ± 8.364.2 ± 9.362.4 ± 8.2Mean age of onset (years) ± SDn/a61.5 ± 9.469.7 ± 8.4Mean disease duration (years) ± SDn/a2.9 ± 1.82.7 ± 2.1Gender: Male:Female% (*n*)43.5:56.5 (37:48)51.9:48.1 (53:49)48.6:51.4 (17:18)Mean absorbance value0.020.130.26Median absorbance value−0.040.020.11Percentage of samples over the 0.11 cut-off point (%)8.82346

Plasma was separated from whole blood samples (5 ml blood with EDTA acting as anti-coagulant) by routine methods, and stored in deep freeze (−80°C) until assay.

Immunoassay protocol {#Sec4}
--------------------

An antibody-sandwich ELISA was developed to measure the TDP-43 concentration in plasma samples. The ELISA plates (96-well PVC assay plates, Iwaki, Japan) were coated by overnight incubation at 4°C with 0.2 μg/ml anti-TDP monoclonal antibody (H00023435-M01, clone 2E2-D3, Abnova Corporation, Taiwan), 100 μl/well, diluted in 200 mM NaHCO~3~ buffer, pH 9.6, containing 0.02% (w/v) sodium azide. The plates were washed 3 times with PBST (PBS (0.01 M phosphate buffer, 0.0027 M potassium chloride and 0.137 M sodium chloride, pH 7.4) containing 0.05% Tween 20), and incubated with 200 μl/well of blocking buffer (PBS containing 2.5% gelatin and 0.05% Tween 20) for 2 h at 37°C. The plates were again washed 3 times with PBST, and 100 μl of the plasma samples to be tested, diluted 1:1 with PBS, were added to each of three wells. After washing 3 times with PBST, 100 μl of the detection antibody, TDP rabbit polyclonal antibody (BC001487, ProteinTech Group, Chicago) diluted to 0.2 μg/ml in blocking buffer, was added per well and the plates were incubated at 37°C for 2 h. After another wash (as before), the plates were incubated with 100 μl/well of goat anti-rabbit secondary antibody coupled to horseradish peroxidase (HRP) (Dako Ltd., Ely, U.K.), diluted 1:10,000 in blocking buffer, at 37°C for 1 h. The plates were then washed again with PBST, before adding 100 μl/well Sure Blue TMB Microwell Peroxidase Substrate (KPL Inc, Maryland, USA) and leaving the colour to develop for 30 min at room temperature. Finally, 100 μl/well of stop solution (0.3 M H~2~SO~4~) was added and absorbance values were read at 450 nm in a Victor^2^ multi-function microtitre plate reader. Net absorbance was calculated by deducting the mean value obtained for a triplicate of "blank" wells containing PBS only.

The antibody-sandwich ELISA using polyclonal TDP-43 antibody (BC001487) as capture antibody was also successful and gave similar signals. However, the monoclonal antibody (2E2-D3) was chosen as the preferred capture antibody as background signals were smaller.

Recombinant TDP-43 protein (MW 54.3 KDa) (AAH01487, 1 -261, Abnova Corporation, Taiwan, with 26 KDa GST tag) was used in the standard curve.

Immunoprecipitation of TDP-43 from plasma {#Sec5}
-----------------------------------------

Dynabeads covalently coupled with recombinant protein A, were derivatised with rabbit polyclonal anti-TDP-43 antibody (BC001487, ProteinTech Group, Chicago) as recommended by the manufacturer (Dynal Biotech LTD.,Wirral, UK). 300 μl plasma was added to the beads and incubated overnight at 4°C. The plasma samples were chosen according to the ELISA results, with one sample giving a high signal and the other a low signal. The beads were then washed three times with 0.1 M phosphate buffer, pH 8.2. Any captured TDP-43 was eluted from the beads by boiling for 10 min in NuPAGE LDS sample buffer (Invitrogen Ltd., UK) and examined by gel electrophoresis and immunoblotting.

Gel electrophoresis and immunoblotting {#Sec6}
--------------------------------------

The protein eluted from the magnetic dynabeads (see above) was separated on NUPAGE Bis-Tris 4-12%, 1 mm gels (Invitrogen). The separated proteins were transferred to nitrocellulose membranes (0.45 μm, Invitrogen) at 30 V, 125 mA for 1 h. Membranes were blocked with 5% Marvel dried skimmed milk, dissolved in PBST for 1 h. The membranes were probed overnight at 4°C with either anti-TDP-43 antibody, rabbit polyclonal (BC001487, ProteinTech Group, Chicago) 1:1,000 in PBST, or anti-TDP-43 mouse monoclonal antibody (H00023435-M01, clone 2E2-D3, Abnova Corporation, Taiwan) 1:1,000 in PBST, as indicated. The membranes were washed three times in PBST, followed by incubation with HRP-conjugated goat anti-rabbit or goat anti-mouse (Dako LTD., Ely, U.K.), 1:10,000 in PBST, as appropriate, for 1 h. The protein bands were visualised using ECL reagents (Pierce, Rockford, IL) as described by the manufacturer.

Statistical analyses {#Sec7}
--------------------

All data were analysed using SPSS v 14.0. Because OD values for FTD and AD patients, as well as control subjects were not normally distributed according to Kolmogorov-Smirnov test, non-parametric Kruskal-Wallis test was used throughout to compare groups, with post hoc Mann-Whitney test being employed when the results of Kruskal-Wallis test yielded significant group differences.

Results {#Sec8}
=======

A standard curve for the ELISA is shown in Fig. [1](#Fig1){ref-type="fig"}. The ELISA data from the plasma samples indicate that in control subjects, in most instances, TDP-43 was barely detectable (mean ± SD, OD = 0.02 ± 0.32), with just 8 individuals (8.8%) having absorbance (optical density or OD) values exceeding 0.11 (Fig. [2](#Fig2){ref-type="fig"}). This value corresponds to the 99% upper confidence level and was subsequently chosen to represent the 'cut off' point of 'normal' TDP-43 values. In AD, TDP-43 was again barely detectable in 79 patients (78%) (Fig. [2](#Fig2){ref-type="fig"}), though OD exceeded 0.11 in 23 patients (22%). In FTD, 16/35 patients (46%) patients had OD value exceeding 0.11 (Fig. [2](#Fig2){ref-type="fig"}). The proportion of patients with OD greater than 0.11 differed significantly across the groups (χ^2^ = 19.8; *P* \< 0.001) with the proportion of patients with OD values greater than 0.11 being significantly higher in both FTD (χ^2^ = 20.4; *P* \< 0.001) and AD (χ^2^ = 5.8; *P* = 0.016) compared to controls, and in FTD compared to AD (χ^2^ = 6.9; *P* = 0.009). Consequently, the mean OD values for control subjects (0.02 ± 0.32) and patients with FTD (0.26 ± 0.52) and AD (0.13 ± 0.33) were significantly different by Kruskal-Wallis test (χ^2^ = 53.2; *P* \< 0.001), with post hoc Mann-Whitney test showing mean values for both FTD and AD groups to be significantly different from controls (*P* \< 0.001), with mean OD in FTD group also being significantly greater (*P* = 0.037) than that in AD.Fig. 1Standard curve for the TDP-43 ELISA (data show mean ± SD)Fig. 2Box-whisker plots for the plasma ELISA results (absorbance values). The length of each *box* represents the interquartile range (75--25%) of the sample, the *solid line* drawn across the *box* the median, the *dashed line* the mean, and outliers are denoted by *dots*. The *dotted line* representing the 0.11 cut-off corresponds to the 99% upper confidence level for the control group

When protein from plasma samples with high levels of TDP-43 (based on ELISA results) was immunocaptured with magnetic Dynabeads coupled to the anti-TDP-43 rabbit polyclonal antibody, and then examined by gel electrophoresis and western blotting employing the anti-TDP-43 monoclonal antibody for detection, only a single band migrating at \~43 kDa was seen (Fig. [3](#Fig3){ref-type="fig"}, lane 2). No specific bands were detected in similarly treated low-reading plasma samples.Fig. 3Immunoblotting results. *Lane 1* molecular weight markers (numbers to left in kDa); *lane 2* protein immunocaptured from a plasma sample with a high ELISA reading

There were no significant correlations between plasma TDP-43 level and age at onset of illness, or duration of illness up to time of sampling, for AD and FTD groups, either when the whole AD or FTD group, or just those individuals with high TDP-43 levels, were considered.

Discussion {#Sec9}
==========

In the present study we have shown for the first time that the TAR DNA-binding protein, TDP-43, can be detected within plasma of normal control people, as well as individuals with neurodegenerative diseases such as AD and FTD. The ELISA data indicate that TDP-43 is present at extremely low concentrations, or is absent, in the vast majority of normal people, and in AD or FTD there are substantial numbers of patients in whom TDP-43 is likewise barely present. However, group comparisons by ELISA reveal a highly significant increase (approximately 13-fold) in mean TDP-43 absorbance levels in FTD compared to controls, whereas in AD the mean TDP-43 absorbance level was about 7-fold increased. The validity of the ELISA method is supported by the immunoblotting results. In accord with the ELISA data, an immunoreactive band migrating at 43 kDa, which corresponds precisely to the molecular weight of full-length TDP-43 \[[@CR2], [@CR24]\] was detected only in the high-reading plasma sample and not in the low-reading sample. This result not only confirms the specificity of the antibody pair employed for the sandwich ELISA, but also shows that the readout from the ELISA accurately reflects the levels of TDP-43 present in plasma.

From histological studies, it is known that about 50% of patients with FTD have ubiquitin/TDP-43-based histology \[[@CR6], [@CR7], [@CR10], [@CR14], [@CR15], [@CR20], [@CR27]\] and consequently it might be expected that a similar proportion of patients with this kind of pathology would be included within the present unselected FTD study group. In the present FTD cohort, there was a highly significant mean increase in plasma TDP-43 absorbance levels, with about 46% patients showing 'high' TDP-43 levels (ie above OD of 0.11 corresponding to 99% upper control limit). On the basis of autopsy studies \[[@CR6], [@CR7], [@CR9]\] such a proportion of patients would have been anticipated if the presence of TDP-43 in plasma is indeed indexing the presence of TDP-43 pathology in brain. Likewise, in AD it is known that about 20--25% patients have TDP-43-based pathology \[[@CR1]\] and again it might be anticipated that within the present group of unselected AD cases, a similar proportion of cases with TDP-43 pathology would exist. In the present AD group 22% patients showed 'high' TDP-43 values, while in most patients no increase was seen. Therefore the proportion of patients showing high plasma TDP-43 levels in both FTD and AD closely match, at least in numerical terms, those proportions that would be predicted to occur from histological studies.

The few elderly control subjects with high TDP-43 levels (8%) may be patients with incipient neurodegenerative disease, most likely AD, since it has long been known that a very high proportion of mentally normal elderly subjects show at autopsy some degree of Alzheimer-type pathological changes in their brains (ie senile plaques and neurofibrillary tangles), and this may, as in AD itself, include some individuals with additional TDP-43 pathology. Indeed, the proportion of control subjects showing raised plasma TDP-43 levels recorded here is similar to the prevalence rate of elderly individuals with mild cognitive impairment. \[[@CR11], [@CR13], [@CR19]\], supporting the view that such individuals might represent cases of early or incipient AD with additional TDP-43 pathological changes.

Although the numerical similarities between the proportions of patients with FTD and AD showing 'high' TDP-43 plasma levels and those displaying TDP-43 pathological changes at autopsy argue that measurement of plasma TDP-43 level can index the presence of TDP-43 pathology within the brain of patients with FTD or AD, we accept that these numerical associations may simply be fortuitous, or may reflect, for example, a compromised blood-brain barrier in FTD and AD, and recognise that the data we have presented here, although intriguing, is still very much preliminary. Present data, and the arguments we have presented based on this data, would be greatly strengthened if autopsy follow-up of patients with AD or FTD with high plasma TDP-43 values were available. However, because the patients investigated here were still in the early or middle stages of their illness when blood samples were taken, this will not be possible for many years to come. An alternative approach would be to compare plasma TDP-43 levels in FTD patients bearing *MAPT* or *PGRN* mutations, since it is known from histological studies that patients with *MAPT* mutations and tauopathy do not show TDP-43 pathological changes in their brains \[[@CR9]\], whereas those with *PGRN* mutation always display TDP-43 pathological changes \[[@CR3], [@CR4], [@CR8], [@CR9], [@CR16], [@CR26], [@CR28]\]. Hence, by the present argument, patients with *MAPT* mutations should show low (normal) plasma TDP-43 levels and those with *PGRN* mutations should show high(er) plasma TDP-43 levels. Unfortunately, within the present cohort of FTD patients there was only one bearer of *PGRN* mutation (in whom the plasma TDP-43 level was raised), and no bearers of *MAPT* mutation, so at present we are not realistically able to address this issue. We are presently aiming to collect further plasma samples from the surviving *MAPT* and *PGRN* mutation bearers within our FTD cohort. Until then, present data suggest, but do not definitively show, that measurement of plasma TDP-43 level might discriminate in life, those patients with FTD or AD with TDP-43 pathology from those without TDP-43 pathology (ie those with tau-based histological changes), even if it does not differentiate between patients with AD or FTD per se.

Because all patients investigated were (when sampled) in early to middle stages of disease it has not been possible so far to follow or deduce how changes in plasma TDP-43 levels might change with disease progression or disease severity. Further studies based on repeat sampling from patients with elevated plasma TDP-43 levels will address this matter.

Although we do not know the biological or functional significance of (the additional) TDP-43 pathology in patients with AD, as with FTD, there may be heuristic (future) management or therapeutic values in being able to predict the presence of TDP-43 changes in such patients. Given the possibility of tau- or TDP-43-based therapies becoming available for patients with AD or FTD, knowing who in AD or FTD is potentially able to benefit from tau and/or TDP-43 based therapy, according to predictive knowledge of underlying histology, would be of considerable practical value.
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